MediWound Ltd. (MDWD)

MediWound Ltd. (MDWD) Healthcare & Pipeline Overview

MediWound Ltd. is a biopharmaceutical company focused on developing and commercializing bio-therapeutic solutions for tissue repair and regeneration, primarily addressing burn care with its lead product NexoBrid, while expanding its pipeline to treat chronic wounds and other dermatological conditions, operating within the competitive biotechnology sector.

What Is the Investment Thesis for MDWD?

MediWound Ltd. presents a focused investment opportunity within the biotechnology sector, driven by its lead product NexoBrid and its pipeline of wound care solutions. The company's potential lies in the continued adoption of NexoBrid in burn treatment, offering a non-surgical alternative for eschar removal. Key growth catalysts include the advancement of EscharEx through clinical trials and its potential commercialization for chronic wound debridement. However, the company's negative profit margin of -140.8% highlights the need for improved financial performance and efficient commercialization strategies. The success of MW005 in treating basal cell carcinoma could further diversify MediWound's product portfolio. Investors should closely monitor the company's ability to achieve profitability, manage its operating expenses, and successfully navigate the regulatory landscape for its pipeline products.

Based on FMP financials and quantitative analysis

MDWD Key Highlights

• Market capitalization of $160.66M, reflecting the company's current valuation in the biotechnology market.
• Gross margin of 19.2%, indicating the profitability of MediWound's products before operating expenses.
• Profit margin of -140.8%, highlighting the company's current challenges in achieving profitability.
• Beta of 0.15, suggesting lower volatility compared to the overall market.
• Focus on innovative bio-therapeutic solutions for tissue repair and regeneration, positioning the company in a specialized segment of the healthcare industry.

Who Are MDWD's Competitors?

MDWD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MDWD's Key Strengths?

• Innovative bio-therapeutic solutions for tissue repair and regeneration.
• Established market presence with NexoBrid for burn treatment.
• Pipeline of products in development for chronic wounds and basal cell carcinoma.
• Experienced management team with expertise in biotechnology and wound care.

What Are MDWD's Weaknesses?

• Negative profit margin, indicating financial challenges.
• Reliance on a limited number of products for revenue generation.
• High research and development expenses.
• Limited commercial infrastructure compared to larger pharmaceutical companies.

What Could Drive MDWD Stock Higher?

• Results from Phase III clinical trials for EscharEx in chronic wound debridement could drive investor interest.
• Continued expansion of NexoBrid sales in existing and new markets.
• Regulatory approvals for MW005 in the treatment of low-risk basal cell carcinoma.

What Are the Key Risks for MDWD?

• Negative return on equity (-67.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approvals for pipeline products.
• Competition from established pharmaceutical companies in the wound care market.
• Product liability claims related to NexoBrid or other products.
• Dependence on key suppliers for manufacturing and distribution.

What Are the Growth Opportunities for MDWD?

• Expansion of NexoBrid Market Share: NexoBrid, MediWound's lead product, has the potential to capture a larger share of the burn treatment market. The global burn care market is projected to reach $3.2 billion by 2027, driven by the increasing incidence of burn injuries and the demand for advanced wound care solutions. By increasing awareness and adoption of NexoBrid in burn centers and hospitals, MediWound can drive revenue growth and establish itself as a leader in burn care. Timeline: Ongoing.
• Advancement of EscharEx for Chronic Wound Debridement: EscharEx, currently in Phase II clinical trials, represents a significant growth opportunity for MediWound. The chronic wound care market is estimated to reach $12.5 billion by 2028, fueled by the rising prevalence of diabetes and other chronic conditions. Successful completion of clinical trials and subsequent commercialization of EscharEx could provide MediWound with a valuable product for addressing the unmet needs in chronic wound care. Timeline: 2-3 years.
• Development of MW005 for Basal Cell Carcinoma: MW005, in Phase I/II clinical trials, targets low-risk basal cell carcinoma, the most common form of skin cancer. The global basal cell carcinoma market is projected to reach $9.8 billion by 2030, driven by the increasing incidence of skin cancer and the demand for non-invasive treatment options. Successful development and commercialization of MW005 could diversify MediWound's product portfolio and expand its presence in the dermatology market. Timeline: 3-5 years.
• Geographic Expansion: MediWound has the opportunity to expand its geographic reach by entering new markets and regions. The global wound care market is growing rapidly in emerging economies, driven by increasing healthcare spending and improving access to healthcare services. By strategically expanding its commercial operations to new markets, MediWound can tap into new revenue streams and diversify its geographic risk. Timeline: Ongoing.
• Strategic Partnerships and Collaborations: MediWound can leverage strategic partnerships and collaborations to accelerate its growth and expand its capabilities. Collaborating with other pharmaceutical companies, research institutions, or healthcare providers can provide access to new technologies, expertise, and resources. These partnerships can help MediWound to develop new products, expand its market reach, and strengthen its competitive position in the biotechnology industry. Timeline: Ongoing.

What Opportunities Does MDWD Have?

• Expansion of NexoBrid market share in burn treatment.
• Successful commercialization of EscharEx for chronic wound debridement.
• Development of MW005 for basal cell carcinoma.
• Strategic partnerships and collaborations to expand capabilities.

What Threats Does MDWD Face?

• Competition from established pharmaceutical companies and biotechnology firms.
• Regulatory hurdles and clinical trial risks.
• Pricing pressures and reimbursement challenges.
• Product liability risks.

What Are MDWD's Competitive Advantages?

• Proprietary bio-therapeutic technology.
• Established market presence with NexoBrid.
• Pipeline of innovative products in development.
• Specialized expertise in wound care and dermatology.

What Does MDWD Do?

Founded in 2000 and headquartered in Yavne, Israel, MediWound Ltd. is a biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative bio-therapeutic solutions for tissue repair and regeneration. The company's flagship product, NexoBrid, is a biopharmaceutical product designed for the removal of eschar, which is dead or damaged tissue, in adult patients with deep partial- and full-thickness thermal burns. NexoBrid is marketed to burn centers and hospital burn units, offering a non-surgical alternative for eschar removal. Beyond NexoBrid, MediWound is actively developing EscharEx, a product that has completed Phase II clinical trials, intended for the debridement of chronic and other hard-to-heal wounds. Additionally, the company is advancing MW005, currently in Phase I/II clinical trials, for the treatment of low-risk basal cell carcinoma. MediWound's focus is on addressing unmet needs in wound care and dermatological conditions through its innovative bio-therapeutic solutions, positioning itself as a key player in the biotechnology industry with a commitment to improving patient outcomes.

What Products and Services Does MDWD Offer?

• Develops bio-therapeutic solutions for tissue repair and regeneration.
• Manufactures novel products for wound care.
• Commercializes products for burn treatment and chronic wound debridement.
• Markets NexoBrid for eschar removal in burn patients.
• Conducts clinical trials for new product development.
• Focuses on addressing unmet needs in wound care and dermatology.

How Does MDWD Make Money?

• Develops and manufactures bio-therapeutic products.
• Markets and sells products directly to hospitals and burn centers.
• Generates revenue through product sales.
• Invests in research and development to expand its product pipeline.

What Industry Does MDWD Operate In?

MediWound Ltd. operates within the biotechnology industry, which is characterized by rapid innovation, intense competition, and high regulatory scrutiny. The market for wound care solutions is driven by the increasing prevalence of chronic diseases, such as diabetes and obesity, which contribute to the development of chronic wounds. The competitive landscape includes both established pharmaceutical companies and smaller biotechnology firms, all vying for market share. MediWound's focus on bio-therapeutic solutions for tissue repair and regeneration positions it within a niche segment of the industry, where innovation and clinical efficacy are key differentiators.

Who Are MDWD's Key Customers?

• Burn centers.
• Hospitals burn units.
• Healthcare providers specializing in wound care.
• Patients with deep partial- and full-thickness thermal burns.

How MediWound Ltd. Is Valued

MediWound Ltd. carries a market capitalization of $160.66M, placing it in the micro-cap category. Relative to its peer group, MDWD's quantitative score of 45/100 is below the peer average of 86/100.

ROE -67%Key Financial Metrics

Return on equity for MediWound Ltd. stands at -67.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -32.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

MediWound Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.51 places it in the grey zone, a middle ground that warrants monitoring.

FY2026 estForward Outlook

Wall Street analysts project MediWound Ltd. revenue of about $24.1M for fiscal 2026, with EPS near $-2.31. The estimate reflects 6 contributing analysts.

Net buyingInsider Activity

Over the past six months, MediWound Ltd. insiders filed 6 SEC Form 4 transactions — 0 sales and 6 purchases. On net that is roughly 10K shares acquired (about $136K) — insiders putting money in tends to read as conviction.

MDWD Financials

MDWD Latest News

MDWD Analyst Consensus

MDWD MoonshotScore

Common Questions About MDWD (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources